Oakworth Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Oakworth Capital’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-263	Closed	-$19K	–	578
2018 Q4	$19K	Hold	263	–	–	﹤0.01%	383
2018 Q3	$22K	Hold	263	–	–	﹤0.01%	386
2018 Q2	$30K	Hold	263	–	–	0.01%	350
2018 Q1	$24K	Hold	263	–	–	0.01%	350
2017 Q4	$13K	Hold	263	–	–	﹤0.01%	433
2017 Q3	$11K	Hold	263	–	–	﹤0.01%	460
2017 Q2	$9K	Hold	263	–	–	﹤0.01%	466
2017 Q1	$8K	Hold	263	–	–	﹤0.01%	479
2016 Q4	$8K	Hold	263	–	–	﹤0.01%	475
2016 Q3	$7K	Buy	+263	New	+$6.11K	﹤0.01%	475

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Oakworth Capital's ENTA Position: Q1 2019 in Review

Oakworth Capital sold out of Enanta Pharmaceuticals (ENTA) in Q1 2019, closing a stake of 263 shares — an estimated $19K sold.

Oakworth Capital first reported a position in ENTA in Q3 2016 and held it in 10 quarters. The position peaked at $30K in Q2 2018. 195 funds tracked by Wall St. Rank hold ENTA as of Q1 2019.

Oakworth Capital reported no remaining Enanta Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Oakworth Capital sold 263 Enanta Pharmaceuticals shares in Q1 2019, an estimated $19K.
Oakworth Capital first reported a position in Enanta Pharmaceuticals in Q3 2016 and held it in 10 quarters.
Oakworth Capital's Enanta Pharmaceuticals position peaked at $30K in Q2 2018.
195 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2019.

Based on Oakworth Capital's 13F filing for Q1 2019, filed 6 May 2019.